Find comprehensive information on Hodgkin lymphoma diagnosis including clinical documentation, medical coding, and healthcare resources. Learn about ICD-10 codes for Hodgkin lymphoma, staging, symptoms, treatment, and pathology reports. Explore resources for healthcare professionals, patients, and caregivers related to Hodgkin lymphoma diagnosis, prognosis, and differential diagnosis. This resource provides guidance on accurate clinical documentation and appropriate medical coding for Hodgkin lymphoma.
Also known as
Hodgkin lymphoma
Malignant neoplasms of lymphoid, hematopoietic and related tissues
Other malignant neoplasms of lymphoid
Includes other specified and unspecified types of lymphoma.
Other and unspecified lymphoma
Includes unspecified malignant lymphoma and other lymphomas.
Personal history of malignant neoplasm
Codes for personal history of Hodgkin lymphoma and related conditions.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the Hodgkin Lymphoma diagnosis confirmed?
When to use each related code
| Description |
|---|
| Hodgkin lymphoma |
| Non-Hodgkin lymphoma |
| Lymphocytic leukemia |
Incorrect coding of the specific Hodgkin lymphoma subtype (e.g., nodular sclerosis, mixed cellularity) impacting reimbursement and treatment planning.
Errors in assigning the Ann Arbor stage (I-IV) due to incomplete documentation of disease extent affecting treatment intensity and prognosis reporting.
Failure to document or code the presence or absence of B symptoms (fever, night sweats, weight loss) influencing risk stratification and treatment decisions.
Q: What are the most effective current treatment protocols for managing stage IIB Hodgkin Lymphoma with bulky mediastinal disease in young adults?
A: Managing stage IIB Hodgkin Lymphoma with bulky mediastinal disease in young adults often requires a multi-modal approach. Current National Comprehensive Cancer Network (NCCN) guidelines recommend chemotherapy regimens such as ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine), BEACOPP (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Oncovin, Procarbazine, Prednisone), or Stanford V, potentially combined with involved-site radiation therapy (ISRT). The choice of regimen and the inclusion of ISRT depends on factors like the International Prognostic Score (IPS), the size of the mediastinal mass, and patient-specific factors like pulmonary function. PET-guided therapy is also increasingly utilized for response assessment and treatment adaptation. Explore how PET scans can inform treatment decisions in Hodgkin Lymphoma and consider implementing strategies for minimizing long-term treatment-related toxicities, especially in young adults. Learn more about the latest clinical trial data informing these treatment protocols.
Q: How can I differentiate between Hodgkin Lymphoma and other lymphoma subtypes, such as T-cell lymphoma, based on biopsy and immunohistochemistry results?
A: Differentiating Hodgkin Lymphoma from other lymphoma subtypes, such as T-cell lymphoma, relies on a combination of histopathology and immunohistochemistry. In Hodgkin Lymphoma, the hallmark finding is the presence of Reed-Sternberg cells (RS cells) and their variants against a background of reactive inflammatory cells. These RS cells typically express CD15 and CD30, but are negative for CD45. In contrast, T-cell lymphomas exhibit a different immunophenotype, often expressing markers such as CD3, CD4, CD5, CD7, or CD8, depending on the specific subtype. Careful evaluation of the biopsy morphology, along with a comprehensive immunohistochemical panel, is crucial for accurate diagnosis. Consider implementing standardized diagnostic algorithms for lymphoma subtyping and explore how advanced imaging techniques, like PET-CT, can aid in staging and assessing treatment response. Learn more about the role of flow cytometry and molecular diagnostics in complex cases.
Patient presents with chief complaints suggestive of Hodgkin lymphoma, including painless lymphadenopathy, typically involving cervical or supraclavicular lymph nodes. Symptoms may also include fatigue, unexplained weight loss, night sweats, pruritus, and intermittent fever. Physical examination reveals palpable, firm, non-tender lymph nodes. Complete blood count may demonstrate anemia, leukocytosis, eosinophilia, or lymphocytopenia. Excisional lymph node biopsy is performed for histopathological evaluation, revealing the presence of Reed-Sternberg cells, confirming the diagnosis of Hodgkin lymphoma. Immunohistochemical staining and flow cytometry are utilized for further characterization of the lymphoma subtype. Staging workup, including computed tomography scans of the chest, abdomen, and pelvis, and positron emission tomography scan, are conducted to assess disease extent and determine the Ann Arbor stage. Bone marrow biopsy may be performed to evaluate bone marrow involvement. Based on the clinical findings and staging results, a diagnosis of Hodgkin lymphoma, classical type or nodular lymphocyte-predominant Hodgkin lymphoma, is established. Treatment plan includes chemotherapy regimens such as ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) or BEACOPP (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone), and may involve radiation therapy depending on the stage and prognostic factors. Patient education regarding treatment options, potential side effects, and follow-up care is provided. Ongoing monitoring for treatment response and recurrence is planned. Medical coding will utilize ICD-10 code C81.x for Hodgkin lymphoma and appropriate CPT codes for procedures performed. Billing will reflect services rendered, including consultations, diagnostic tests, and treatment administration.